openPR Logo
Press release

Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave

03-26-2024 11:04 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate

Biotech Stocks Taking Centerstage
As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are gaining prominence for their targeted approach to cancer treatment. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate in the eyes of investors and industry giants alike.

Actinium Pharmaceuticals (NYSE:ATNM) recently announced a pivotal strategic initiative to escalate the production of Ac-225 using a proprietary cyclotron-based method, as detailed in a press release from March 11, 2024. This method not only promises high-purity Ac-225 but also boasts the potential for significantly lower costs and higher yields compared to the traditional Thorium-229 generator method. The significance of this development cannot be overstated, given the isotope's remarkable ability to kill targeted cancer cells without known resistance or repair mechanisms, courtesy of its high linear energy transfer and capacity for inducing double-strand breaks in DNA.

This initiative is not merely about enhancing Actinium's manufacturing prowess; it's an outright game-changer. The company's intellectual property portfolio, encompassing 5 issued U.S. patents and 49 international patents, coupled with extensive technical know-how, places Actinium at the forefront of a radiopharmaceutical revolution. With the capability to produce up to 100 mCi of Ac-225 per production cycle at a cost estimated to be 10 to 20 times lower than current methods, and with radiochemical purity exceeding 99%, Actinium's production technology sets a new standard in the industry.

The broader context of this development is the recent flurry of acquisitions in the radiopharma space, notably AstraZeneca's (NASDAQ:AZN) acquisition of Fusion Pharma and Bristol Meyers's (NYSE:BMY) $4.1 billion acquisition of RayzeBio for its Ac-225 pipeline, highlighting the strategic importance of alpha emitters. Furthermore, Lilly's acquisition of POINT Biopharma for $1.4 billion emphasizes the burgeoning interest in targeted radiotherapies. In this landscape, Actinium's strategic initiative underscores its scarcity value and technological edge, making it a compelling target for companies vying for dominance in next-generation cancer therapies.

For investors and traders, the allure of Actinium Pharmaceuticals is twofold: the immediate potential for growth driven by its advanced manufacturing capabilities and the long-term prospect of becoming a buyout target in an industry segment marked by high-stakes acquisitions. Actinium's focus on a niche yet explosively growing segment of radiopharmaceuticals, coupled with its innovative production method, positions it as a strategic asset in the race to harness the power of targeted cancer therapies.

Actinium Pharmaceuticals (ATNM) potentially represents an unparalleled investment opportunity, not just for its promising pipeline but for its groundbreaking approach to the production of Ac-225. As the radiopharma sector continues to attract significant interest and investment, Actinium stands out as a company with both immediate impact and strategic value, making it an attractive proposition for those looking to invest in the forefront of medical innovation. The company's recent strategic initiative marks a significant milestone, potentially catalyzing its journey towards becoming a coveted acquisition target amidst the radiopharmaceutical acquisition wave.

On Monday, the biotech sector displayed a mix of performances among its leading stocks. Novo Nordisk A/S (NYSE:NVO) saw a modest increase of 0.29, reaching 129.05 (+0.23%), with trading volume at 3.305M against an average of 5.126M, showcasing a market cap of 577.833B and a PE ratio of 47.27. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) slightly rose by 0.37 to 416.03 (+0.09%), with a trading volume of 721,971 compared to its average of 1.303M, holding a market valuation of 107.464B and a PE ratio of 29.97. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) experienced a decrease, dropping by 6.15 to 961.09 (-0.64%), with its volume at 315,100 versus an average of 522,886, and a market cap of 105.491B, with a PE ratio of 27.67. Moderna, Inc. (MRNA) notably surged by 4.95 to 110.38 (+4.70%), trading 3.54M shares against an average of 4.459M, resulting in a market cap of 42.262B. argenx SE (NASDAQ:ARGX) fell by 4.26 to 398.42 (-1.06%), with a volume of 179,831 and an average of 362,027, and a market cap of 23.867B. BioNTech SE (NASDAQ:BNTX) increased by 1.17 to 93.00 (+1.27%), with a trading volume of 371,817 compared to an average of 698,642, and a market capitalization of 22.109B, alongside a PE ratio of 22.20.

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com [https://www.abnewswire.com/adminnew/InvestorBrandMedia.com]/disclaimer/. InvestorBrandMedia.com has been compensated five hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM for March 20th, 2024. We own zero shares of ATNM. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like "believes," "anticipates," "estimates," "expects," "projects," "intends," or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person's use of or access to this content.

Sources:

https://www.tipranks.com/news/the-fly/actinium-pharmaceuticals-price-target-raised-to-30-from-20-at-maxim

https://finance.yahoo.com/news/actinium-pharmaceuticals-launches-actinium-225-113000769.html

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=actinium-pharmaceuticals-atnm-a-prime-buyout-candidate-amidst-a-radiopharma-acquisition-wave]
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave here

News-ID: 3442226 • Views:

More Releases from ABNewswire

Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more. It is now a lifestyle choice. Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better. In areas with seasonal weather, where people can be outside for most of the year, homeowners
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecedented Demand from Motor City Small Business Owners
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape. The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Property Maintenance Demand
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services. Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Movers as Leading Alternative to Traditional Van Line Brokers
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards. A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading

All 5 Releases


More Releases for Actinium

Hematopoietic Stem Cell Transplantation Market to Reach New Heights in Growth by …
Hematopoietic Stem Cell Transplantation Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Sanofi, Actinium Pharma, Medexus Pharma, medac Pharma, Actinium Pharma The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics. DelveInsight's "Hematopoietic Stem
How Mobile Technology is Influencing the Actinium Isotope Market
Actinium Isotope Market size was valued at USD 1.2 Billion in 2024 and is forecasted to grow at a CAGR of 8.7% from 2026 to 2033, reaching USD 2.5 Billion by 2033. Actinium Isotope Market Future Scope The Actinium Isotope Market was valued at approximately USD 15 million in 2022, with a compound annual growth rate (CAGR) of around 7.5% expected over the forecast period from 2023 to 2030. This market's growth
Actinium-225 Research:CAGR of 20.6% during the forecast period
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Actinium-225- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years. The global
Hematopoietic Stem Cell Transplantation Market to Expand Significantly by 2034, …
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics. DelveInsight's "Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as
Actinium-225 Market: Size, Share, Growth, Analysis, Key Players, Revenue, | Valu …
Actinium-225 Market Size The global Actinium-225 market was valued at US$ 0.6 million in 2023 and is anticipated to reach US$ 1.6 million by 2030, witnessing a CAGR of 15.2% during the forecast period 2024-2030. View sample report https://reports.valuates.com/request/sample/QYRE-Auto-35M13954/Global_Actinium_225_Market_Research_Report_2023 Actinium-225 Market Actinium-225 (225Ac, Ac-225) is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life of 10 days, and is an intermediate decay product in the neptunium series (the decay chain starting
Hematopoietic Stem Cell Transplantation Market Growth to Accelerate in Forecast …
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics. DelveInsight's "Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as well as